-
ABOUT USAffiliated to SSY Group Limited, Hebei Guangxiang Technology Co., Ltd., is a high-tech enterprise specializing in drug research and technology development.
-
INNOVATIONSSY Group Limited has built a relatively perfect scientific research and innovation system with the synergy between “industry, academia, research and application” based on multi-disciplinary integration and multi-directional combination.
-
SUBORDINATEThe group has decided to establish research institutes in its subsidiaries, Hebei Ghuangxiang Drug Research Institute, Jiangsu Best Medical Material Research Institute, and Hebei Hanlin Biological Research Institute.
-
RECRUITWe actively establish a joint talent cultivation mechanism between schools and enterprises, and currently have over 500 high-level talents in various fields such as drug research, analysis, and clinical practice.
-
CONTACTWe will continue to strengthen innovation-driven development, vigorously promote the integration of production and research, constantly improve the five domains: new drugs, biological drugs, traditional Chinese medicine, generic drugs and APIs.
Shijiazhuang Sihua Pharmaceutical Group’s Compound Electrolyte Injection (II) has simultaneously received approval for two specifications.
Category:
Time：2023-04-21
On April 20, two new specifications of Compound Electrolyte Injection (II)—1000 ml and 500 ml—submitted by Shijiazhuang Fourth Pharmaceutical Group simultaneously received drug production registration approvals from the National Medical Products Administration. Among these, the 1000 ml specification is the first in China to be deemed as having passed the consistency evaluation, while the 500 ml specification is the second in China to receive such a designation. As of now, the group has had 21 new products approved this year, marking the beginning of a concentrated period of R&D and innovation achievements.
On April 20, two new specifications of Compound Electrolyte Injection (II)—1000 ml and 500 ml—submitted by Shijiazhuang Fourth Pharmaceutical Group simultaneously received drug production registration approvals from the National Medical Products Administration. Among these, the 1000 ml specification is the first in China to be deemed as having passed the consistency evaluation, while the 500 ml specification is the second in China to receive such a designation. As of now, the group has had 21 new products approved this year, marking the beginning of a concentrated period of R&D innovation and product launches.
It is reported that Compound Electrolyte Injection (Ⅱ) is primarily used to treat isotonic dehydration accompanied by or expected to develop into acidosis, and to replenish the loss of extracellular fluid.
Following the approval of 16 new products in the first quarter, in April, the group saw the approval of five additional new products: the active pharmaceutical ingredient telavancin phosphate, terbutaline sulfate solution for nebulization (1 ml: 2.5 mg), peritoneal dialysis solution (lactate G-2.5%), and compound electrolyte injection (II) (1000 ml and 500 ml). The continually expanding lineup of new products will further enhance the company’s product structure and provide fresh impetus for building competitive advantages.
Keywords:
Recommended News
Share to
SERVICE HOTLINE
Mobile site
E code
Business license